title: Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
abstract: We present a case of perforating folliculitis in a patient treated with nilotinib, a kinase inhibitor. A 48-year-old man presented with a severely pruritic follicular rash for several months that started after reaching a complete molecular response of his myeloid chronic while treated with nilotinib. Clinical examination showed predominantly follicular pinpoint papules on trunk and proximal extremities and a biopsy showed a slightly dilated hair follicle with a focal disruption of the infundibular follicular epithelium. Other diseases related with perforating folliculitis were ruled out. The temporary relationship between the treatment and the appearance of the lesions suggests some pathogenic role of nilotinib. Relationship with nilotinib is also supported by previous similar cases related with sorafenib therapy. Both drugs inhibit c-kit and PDGF-R. PDGF-R has been previously involved in murine and human in vitro models of hair follicle cycle. So, our case supports in vivo the previous evidence of the importance of PDGF-R, a kinase, in the normal hair follicle development.
authors.affiliation: *Contrato Río Hortega del ISCIII, Fundación de Investigación De La Princesa, Madrid, Spain; Departments of †Hematology, ‡Dermatology, §Pathology, Hospital Universitario de La Princesa, Madrid, Spain; ‖Department of Dermatology, Fundación Jimenez Diaz, Madrid, Spain.
authors.forename: Mar
authors.initials: M
authors.lastname: Llamas-Velasco
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Steegmann
authors.forename: Raquel
authors.initials: R
authors.lastname: Carrascosa
authors.forename: Javier
authors.initials: J
authors.lastname: Fraga
authors.forename: Amaro
authors.initials: A
authors.lastname: García Diez
authors.forename: Luis
authors.initials: L
authors.lastname: Requena
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides / Q000008:administration & dosage; D000069439:Dasatinib; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology*; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology; D018859:Hair Follicle / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013844:Thiazoles / Q000008:administration & dosage
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib